Moderna Inc (MRNA) concluded trading on Thursady at a closing price of $99.44, with 11.31 million shares of worth about $1.13 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -14.45% during that period and on Thursady the price saw a gain of about 13.53%. Currently the company’s common shares owned by public are about 385.00M shares, out of which, 334.69M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 239 times over the past 12 months. They bought 1,433,481 shares in 56 of the transactions. In 183 selling transactions, insiders dumped 1,581,198 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stock saw a price change of 15.70% in past 5 days and over the past one month there was a price change of -2.43%. Year-to-date (YTD), MRNA shares are showing a performance of -0.01% which decreased to -37.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.55 but also hit the highest price of $163.24 during that period. The average intraday trading volume for Moderna Inc shares is 4.76 million. The stock is currently trading 4.62% above its 20-day simple moving average (SMA20), while that difference is up 3.02% for SMA50 and it goes to -4.22% lower than SMA200.
Moderna Inc (NASDAQ: MRNA) currently have 385.00M outstanding shares and institutions hold larger chunk of about 66.13% of that.
The stock has a current market capitalization of $37.91B and its 3Y-monthly beta is at 1.63. It has posted earnings per share of -$9.34 in the same period. It has Quick Ratio of 2.35 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MRNA, volatility over the week remained 6.28% while standing at 4.56% over the month.
Analysts are in expectations that Moderna Inc (MRNA) stock would likely to be making an EPS of -$0.9 in the current quarter, while forecast for next quarter EPS is -$2.62 and it is -$6.34 for next year. For the current quarter EPS, analysts have given the company a lowest target -$2.64 which is $3.13 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $3.61 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 44.27% while it is estimated to increase by 31.64% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on January 02, 2024 offering an Outperform rating for the stock and assigned a target price of $142 to it. Coverage by Canaccord Genuity stated Moderna Inc (MRNA) stock as a Hold in their note to investors on November 29, 2023, suggesting a price target of $82 for the stock. On November 03, 2023, HSBC Securities Upgrade their recommendations, while on November 02, 2023, Deutsche Bank Downgrade their ratings for the stock with a price target of $60. Stock get a Market perform rating from TD Cowen on August 04, 2023.
